Navigation Links
Galectin Therapeutics Exclusive Interview for the Interlinked Investment News Channel on InterlinkedTV
Date:12/2/2013

(PRWEB) December 02, 2013

Galectin Therapeutics was one of the presenting companies interviewed at the recent FSXinterlinked Investment Conference, held at the Ritz Carlton in Marina Del Rey, California.

During the interview Galectin Therapeutics Executive Chairman, Jim Czirr, said "Galectin Therapeutics is a pharmaceutical company. We are working on drugs to treat untreatable disease at the moment. Diseases like nash, fatty liver disease with fibrosis, cirrhosis of the liver, as well as cancer. This protein called galectin is implicated in those diseases and is responsible for the advancement of the diseases. By inhibiting them or by blocking them we are able to affect the disease in a positive way and improve the patient’s life. In the case of fibrosis, we have evidence that we can reverse it, in the case of cancer, we show great improvement in immune system function with our product."

The interview was conducted by FSXinterlinked Investment Conference Host, Michael Fugler, and is available on the FSXinterlinked channel on InterlinkedTV and more information is available at Galectin Therapeutics’ website.

Galectin Therapeutics, formerly Pro-Pharmaceuticals, is a development-stage company, engages in the discovery and development of therapeutics for the treatment of cancer, liver, microbial, and inflammatory diseases.

About FSXinterlinked Investment Conference
FSXinterlinked is the premier investment conference organization in the United States. Founded as Financial Services Exchange (FSX) in 1983, it is a national organization comprised of independent FINRA broker/dealer firms and private equity fund managers. With quarterly investment conferences hosted throughout the U.S., FSXinterlinked creates a forum for emerging growth companies seeking capital to present to a nationwide network of financial investment professionals.

The FSXinterlinked network of independent broker/dealers has a combined sales force of thousands of accredited investors looking to invest in companies of all sizes and industries. To date, more than $3 billion has been raised for presenting companies through the FSXinterlinked network. FSXinterlinked’s exclusive network of FINRA firms makes the investment conferences the ideal setting for private and public companies seeking mezzanine financing, funding for private placements, IPOs, secondary financing and pipes, exposure, and more. For more information, visit http://www.fsxinterlinked.com/.

Interlinked is a global investment community of accredited investors, emerging growth companies, and resource partners. Interlinked offers an efficient way for companies to maximize exposure and access a private network of funding sources and verified service providers. For investors, Interlinked provides a secure environment to find, vet and engage companies, and communicate with members. Interlinked gives members exclusive access to a proprietary investment platform, which integrates virtual data rooms, video news, a service provider marketplace, an event directory, and customized marketing services, including email marketing, video production, public relations and more. For more information, visit: http://www.interlinked.com/.

Safe Harbor Statement
This press release may contain information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release, including words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date subsequent to the date of this press release.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11377501.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Targeted therapeutics for colon cancer to be presented at AACR meeting
2. The Ludwig Institute for Cancer Research announces launch of iTeos Therapeutics SA
3. FORMA Therapeutics teams with TGen Drug Development
4. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
5. Research shows potential of microneedles to target therapeutics to the back of the eye
6. Cancer vaccine Special Focus series published in Human Vaccines & Immunotherapeutics
7. Scientist receives $2.8 Million to study cell signaling mechanism and develop potential therapeutics
8. Ontario Genomics Institute invests in stem cell technology at Tissue Regenerative Therapeutics
9. Liver Diseases Therapeutics Market - New Industry Research Report Published by Transparency Market Research
10. Global Peptide Therapeutics Market - New Market Research Report Published by Transparency Market Research
11. Corena Therapeutics Launched Coresatin, a Nonsteroidal Cream Used to Treat Critical Skin Conditions and Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... ... Remember the old saying “rub some dirt on it”? Perhaps you should try ... Clay” the health benefits of integrating clay into a daily diet are numerous, as ... motivational speaker, Perry A~ has since dedicated her life to learning about the benefits ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... wide variety of organizations. DocuSyst provides a cloud hosted environment for FileHold ... installations include integration with various 3rd party applications using the FileHold web services ...
(Date:2/8/2016)... ... 2016 , ... GrassrootsHealth published data from its D*action public ... in the GrassrootsHealth cohort with substantially higher vitamin D levels than a cohort ... states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits of vitamin ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... TopConsumerReviews.com recently ... in Mole removal products. , Moles are derived from a cluster of melanin when ... all the wrong places and create a lifetime of embarrassment. Historically, mole removal ...
(Date:2/8/2016)... ... , ... Guruji Mahendra Kumar Trivedi is offering 3 days of accelerated personal ... birthday on February 10th. During this time, people can achieve better health, greater ... people from over 40 different countries as an “ordinary man with an extraordinary gift.” ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... injectable drug delivery systems, today announced that it will release ... December 31, 2015 after market close on February 9, 2016. ... call to discuss these financial results.    About ... --> About Unilife Corporation ...
(Date:2/8/2016)... NORTHBROOK, Ill. , Feb. 8, 2016  Astellas Pharma ... today announced the promotion of James Robinson as ... the company,s operations in North and South America ... president, Astellas Pharma US, representing the commercial organization in ... assumed in 2013. Masao Yoshida , who ...
(Date:2/8/2016)... Palatin Technologies, Inc. (NYSE MKT: PTN), ... for the treatment of diseases with significant unmet ... the United States Patent and Trademark Office (USPTO) ... Patent Application Serial Number 14/313,258 (the ,258 application).  ... female sexual dysfunction using the formulation and dose ...
Breaking Medicine Technology: